NCT05432947View on ClinicalTrials.gov

68Ga-P16-093 and 18F-FDG PET/CT Imaging in the Same Group of Clear Cell Renal Cell Carcinoma Patients

NACompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

April 14, 2022

Primary Completion Date

September 4, 2022

Study Completion Date

September 15, 2022

Conditions
Clear Cell Renal Cell Carcinoma
Interventions
DRUG

68Ga-P16-093

Intravenous injection of 68Ga-P16-093 with a dosage of 1.8-2.2 MBq (0.05-0.06 mCi)/kg.

DRUG

18F-FDG

Intravenous injection of 18F-FDG with a dosage of 5.55 MBq (0.15 mCi)/kg.

Trial Locations (1)

100730

Peking Union Medical College Hospital, Beijing

All Listed Sponsors
lead

Peking Union Medical College Hospital

OTHER